Bayer and Northpond Ventures Lead USD $55 Million Series A Financing Round for Triumvira Immunologics
LEVERKUSEN, Germany & AUSTIN, Texas–(BUSINESS WIRE)–Triumvira Immunologics Inc. (“Triumvira”), a privately-held biopharmaceutical company developing a novel platform for engineering T-cells to attack cancers, successfully completed a USD $55 million...Read More >>